Invitrogen™ Human Fibronectin ELISA Kit

Description

The Human Fibronectin ELISA quantitates Hu Fibronectin in human serum, plasma, urine or cell culture medium. The assay will exclusively recognize both natural and recombinant Hu Fibronectin. Principle of the method The Human Fibronectin solid-phase sandwich ELISA (enzyme-linked immunosorbent assay) is designed to measure the amount of the target bound between a matched antibody pair. A target-specific antibody has been pre-coated in the wells of the supplied microplate. Samples, standards, or controls are then added into these wells and bind to the immobilized (capture) antibody. The sandwich is formed by the addition of the second (detector) antibody, a substrate solution is added that reacts with the enzyme-antibody-target complex to produce measurable signal. The intensity of this signal is directly proportional to the concentration of target present in the original specimen. Rigorous validation Each manufactured lot of this ELISA kit is quality tested for criteria such as sensitivity, specificity, precision, and lot-to-lot consistency. See manual for more information on validation.

Fibronectin is a disulfide-bonded dimer with a molecular weight range of 230-250 kDa. In the extracellular matrix of several connective tissues and vessels, fibronectin is present as an insoluble protein that is extensively cross-linked by interchain disulfide bonds forming high molecular mass polymers. Fibronectin is most abundant during embryonic development and tissue remodeling. Fibronectin is also present at high concentrations as a soluble plasma protein. Fibronectin is organized as a linear series of repeating modules which form domains for interaction with fibronectin itself, other matrix components (e.g. collagen and heparin) and receptors on cells (e.g. integrins). Fibronectin is present in a soluble dimeric form in plasma, and in a dimeric or multimeric form at the cell surface and in extracellular matrix. Fibronectin is involved in cell adhesion and migration processes including embryogenesis, wound healing, blood coagulation, host defense, and metastasis. Fibronectin has been implicated in carcinoma development in lung cancer. Further, Fibronectin expression is increased especially in non-small cell lung carcinoma. The adhesion of lung carcinoma cells to Fibronectin enhances tumorgenecity and confers resistance to apoptosis induced by standard chemotherapeutic agents. The gene encoding Fibronectin has three regions subject to alternative splicing, with the potential to produce 20 different transcript variants. However, the full-length nature of some Fibronectin variants has not been determined.